Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
CC transcript
|
|
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/07/2023 |
4
| Garg Pushkal (CMO & EVP Dev & Med Affairs) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 4,518 shares
@ $0
Granted 3,109 shares
@ $0
Sold 658 shares
@ $184.7, valued at
$121.5k
Sold 1,593 shares
@ $185.54, valued at
$295.6k
Sold 945 shares
@ $186.39, valued at
$176.1k
Sold 86 shares
@ $187.37, valued at
$16.1k
Sold 15 shares
@ $188.4, valued at
$2.8k
Sold 164 shares
@ $189.31, valued at
$31k
Sold 3,112 shares
@ $183.58, valued at
$571.3k
Sold 814 shares
@ $184.65, valued at
$150.3k
Sold 240 shares
@ $185.32, valued at
$44.5k
|
|
| 08/07/2023 |
4
| Poulton Jeffrey V. (EVP, CFO) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 4,518 shares
@ $0
Granted 3,109 shares
@ $0
Sold 658 shares
@ $184.7, valued at
$121.5k
Sold 1,593 shares
@ $185.54, valued at
$295.6k
Sold 944 shares
@ $186.39, valued at
$176k
Sold 86 shares
@ $187.37, valued at
$16.1k
Sold 15 shares
@ $188.4, valued at
$2.8k
Sold 164 shares
@ $189.31, valued at
$31k
|
|
| 08/07/2023 |
4
| Greenstreet Yvonne (CEO) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 5,082 shares
@ $0
Granted 3,859 shares
@ $0
Sold 771 shares
@ $184.7, valued at
$142.4k
Sold 1,869 shares
@ $185.54, valued at
$346.8k
Sold 1,107 shares
@ $186.39, valued at
$206.3k
Sold 101 shares
@ $187.37, valued at
$18.9k
Sold 17 shares
@ $188.4, valued at
$3.2k
Sold 192 shares
@ $189.31, valued at
$36.3k
|
|
| 08/07/2023 |
4
| Vaishnaw Akshay (President) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 5,082 shares
@ $0
Granted 3,859 shares
@ $0
Sold 771 shares
@ $184.7, valued at
$142.4k
Sold 1,869 shares
@ $185.54, valued at
$346.8k
Sold 1,107 shares
@ $186.39, valued at
$206.3k
Sold 101 shares
@ $187.37, valued at
$18.9k
Sold 17 shares
@ $188.4, valued at
$3.2k
Sold 192 shares
@ $189.31, valued at
$36.3k
|
|
| 08/04/2023 |
4
| BONNEY MICHAEL W (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Sold 300 shares
@ $181.08, valued at
$54.3k
Sold 500 shares
@ $182.45, valued at
$91.2k
Sold 560 shares
@ $183.75, valued at
$102.9k
Sold 1,535 shares
@ $184.89, valued at
$283.8k
Sold 1,714 shares
@ $185.99, valued at
$318.8k
Sold 1,389 shares
@ $187.04, valued at
$259.8k
Sold 450 shares
@ $187.71, valued at
$84.5k
Exercised 22,477 restricted stock units
@ $0 |
|
| 05/19/2023 |
4
| PYOTT DAVID E I (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 3,454 options to buy
@ $189.87, valued at
$655.8k
|
|
| 05/19/2023 |
4
| Sigal Charles Elliott (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 3,454 options to buy
@ $189.87, valued at
$655.8k
|
|
| 05/19/2023 |
4
| BRANDICOURT OLIVIER (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 3,454 options to buy
@ $189.87, valued at
$655.8k
|
|
| 05/19/2023 |
4
| HAMBURG MARGARET A (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 3,454 options to buy
@ $189.87, valued at
$655.8k
|
|
| 05/19/2023 |
4
| Reitan Colleen F (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 3,454 options to buy
@ $189.87, valued at
$655.8k
|
|
| 05/19/2023 |
4
| SCHULMAN AMY W (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 3,454 options to buy
@ $189.87, valued at
$655.8k
|
|
| 05/19/2023 |
4
| Ausiello Dennis A (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 3,454 options to buy
@ $189.87, valued at
$655.8k
|
|
| 05/19/2023 |
4
| Fanucci Marsha (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 3,454 options to buy
@ $189.87, valued at
$655.8k
|
|
| 05/19/2023 |
4
| BONNEY MICHAEL W (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 3,454 options to buy
@ $189.87, valued at
$655.8k
|
|
| 05/19/2023 |
4
| SHARP PHILLIP A (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 3,454 options to buy
@ $189.87, valued at
$655.8k
|
|
| 04/28/2023 |
4
| Greenstreet Yvonne (CEO) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 16,952 shares
@ $0
Sold 628 shares
@ $193.18, valued at
$121.3k
Sold 2,898 shares
@ $193.93, valued at
$562k
Sold 3,225 shares
@ $194.94, valued at
$628.7k
Sold 331 shares
@ $195.65, valued at
$64.8k
Sold 533 shares
@ $197.08, valued at
$105k
|
|
| 04/28/2023 |
4
| Poulton Jeffrey V. (EVP, CFO) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 3,277 shares
@ $0
Sold 81 shares
@ $193.18, valued at
$15.6k
Sold 372 shares
@ $193.93, valued at
$72.1k
Sold 414 shares
@ $194.94, valued at
$80.7k
Sold 42 shares
@ $195.65, valued at
$8.2k
Sold 68 shares
@ $197.08, valued at
$13.4k
|
|
| 04/28/2023 |
4
| Tanguler Tolga (EVP, Chief Commercial Officer) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 3,277 shares
@ $0
Sold 122 shares
@ $193.18, valued at
$23.6k
Sold 562 shares
@ $193.93, valued at
$109k
Sold 625 shares
@ $194.94, valued at
$121.8k
Sold 64 shares
@ $195.65, valued at
$12.5k
Sold 103 shares
@ $197.08, valued at
$20.3k
|
|
| 04/28/2023 |
4
| Vaishnaw Akshay (President) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 5,312 shares
@ $0
Sold 197 shares
@ $193.18, valued at
$38.1k
Sold 910 shares
@ $193.93, valued at
$176.5k
Sold 1,013 shares
@ $194.94, valued at
$197.5k
Sold 104 shares
@ $195.65, valued at
$20.3k
Sold 168 shares
@ $197.08, valued at
$33.1k
|
|
| 04/28/2023 |
4
| Garg Pushkal (CMO & EVP Dev & Med Affairs) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 4,294 shares
@ $0
Sold 151 shares
@ $193.18, valued at
$29.2k
Sold 700 shares
@ $193.93, valued at
$135.8k
Sold 779 shares
@ $194.94, valued at
$151.9k
Sold 80 shares
@ $195.65, valued at
$15.7k
Sold 129 shares
@ $197.08, valued at
$25.4k
Sold 204 shares
@ $195.46, valued at
$39.9k
Sold 103 shares
@ $196.62, valued at
$20.3k
Sold 715 shares
@ $198.03, valued at
$141.6k
Sold 385 shares
@ $199.54, valued at
$76.8k
Sold 955 shares
@ $200.35, valued at
$191.3k
|
|
| 03/09/2023 |
4
| KELLOGG PETER N (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 4,948 options to buy
@ $194.34, valued at
$961.6k
|
|
| 03/09/2023 |
3
| KELLOGG PETER N (Director) has filed a Form 3 on ALNYLAM PHARMACEUTICALS, INC. |
| 03/07/2023 |
4
| Garg Pushkal (CMO & EVP Dev & Med Affairs) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Sold 18,072 shares
@ $200, valued at
$3.6M
Exercised 2,500 options to buy
@ $96.45, valued at
$241.1k
|
|
| 03/01/2023 |
4
| Greenstreet Yvonne (CEO) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 17,763 restricted stock units
@ $0
Granted 36,775 options to buy
@ $190.01, valued at
$7M
|
|
| 03/01/2023 |
4
| Vaishnaw Akshay (President) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 5,790 restricted stock units
@ $0
Granted 11,986 options to buy
@ $190.01, valued at
$2.3M
|
|
| 03/01/2023 |
4
| Garg Pushkal (CMO & EVP Dev & Med Affairs) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 5,724 restricted stock units
@ $0
Granted 11,850 options to buy
@ $190.01, valued at
$2.3M
|
|
| 03/01/2023 |
4
| Poulton Jeffrey V. (EVP, CFO) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 5,724 restricted stock units
@ $0
Granted 11,850 options to buy
@ $190.01, valued at
$2.3M
|
|
| 03/01/2023 |
4
| Tanguler Tolga (EVP, Chief Commercial Officer) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 5,000 restricted stock units
@ $0
Granted 10,352 options to buy
@ $190.01, valued at
$2M
|
|
| 03/01/2023 |
4
| Franchini Indrani Lall (EVP, CLO & Secretary) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 2,632 restricted stock units
@ $0
Granted 5,449 options to buy
@ $190.01, valued at
$1M
|
|
| 02/27/2023 |
4
| SCHULMAN AMY W (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Exercised 136 restricted stock units
@ $0 |
|
| 02/27/2023 |
4
| PYOTT DAVID E I (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Exercised 136 restricted stock units
@ $0 |
|
| 02/27/2023 |
4
| HAMBURG MARGARET A (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Exercised 136 restricted stock units
@ $0 |
|
| 02/27/2023 |
4
| Fanucci Marsha (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Exercised 136 restricted stock units
@ $0 |
|
| 02/27/2023 |
4
| Ausiello Dennis A (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Exercised 136 restricted stock units
@ $0 |
|
|
|
|